enzastaurin
Roche’s Columvi improves survival in large B-cell lymphoma
Approximately 160,000 people are diagnosed with this aggressive form of cancer each year
Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma
This is the most common type of non-Hodgkin lymphoma worldwide
Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma
The recommendation for the subcutaneous formulation follows encouraging trial data
Roche’s fixed-duration lymphoma treatment approved by European Commission
Approximately 36,000 people are diagnosed with DLBCL each year in Europe
ADC Therapeutics pauses enrolment in phase 2 lymphoma study following patient deaths
Zynlonta was being evaluated along with rituximab in unfit or frail patients with DLBCL
Lilly restructures in preparation for Alzheimer’s drug launch
As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration
Lilly restructures in preparation for Alzheimer’s drug launch
As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration
FDA sets January decision date for Xalkori in ALK-positive lymphoma
FDA submission is based on results from ADVL0912 and A8081013 studies
NICE recommends Roche’s Polivy for B-cell lymphoma
Cost-effectiveness agency approves drug following initial rejection earlier this year
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
The five-year deal includes Sitryx’ two lead projects
EU grants conditional approval to Roche’s lymphoma drug Polivy
Drug demonstrated a 40% complete response rate in trial
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
Will pay $750m upfront for co-commercialisation rights